Key Highlights

  • Haleon PLC (LSE:HLN) publishes its third-quarter 2026 trading statement on Thursday 29 October.
  • Full-year guidance targets organic revenue growth of 3% to 5% and high single-digit adjusted operating profit growth.
  • First-quarter organic growth was 2.2%, held back by a weak cold and flu season, with growth expected to accelerate later in the year.
  • Investors are watching North America, Oral Health and emerging markets after GSK's slide weighed on healthcare sentiment.

Why Haleon Is in Focus Today

Haleon PLC (LSE:HLN), the consumer healthcare group behind Sensodyne, Panadol, Centrum and Voltaren, is in focus on 28 October 2026 as investors prepare for its third-quarter trading statement on Thursday 29 October. The update arrives a day after GSK, its former parent, fell about 4.8% on weaker vaccine sales, leaving healthcare investors on alert for any further disappointments.

Consumer staples were broadly out of favour on Budget day, with Unilever also falling despite upgraded volume guidance. That makes Haleon's update an important test of whether defensive consumer names can regain investor support.

Guidance for 2026

Haleon (LSE:HLN) expects organic revenue growth of 3% to 5% in 2026 and high single-digit adjusted operating profit growth at constant currency. The company has also guided to net interest of about £255 million and an adjusted effective tax rate of about 24.5%.

Over the medium term, Haleon targets 4% to 6% annual organic revenue growth and high single-digit adjusted operating profit growth, supported by gross margin expansion from supply chain productivity. Management sees optimal leverage at around 2.5 times net debt to adjusted EBITDA.

A Slow Start to the Year

In the first quarter, organic revenue growth was 2.2%, with price up 2.4% and volume down 0.2%. A weak cold and flu season was estimated to have cut growth by about 1.3 percentage points. North America returned to growth with a 1.0% increase despite the soft season, while emerging markets grew 4.3%, reflecting a weaker economic backdrop in places such as Brazil.

Management said it expected growth to accelerate through the rest of the year. The third quarter will show whether that acceleration is under way, particularly in respiratory health as the new cold and flu season begins.

Oral Health Leads the Way

Oral Health has been Haleon's most consistent growth engine, with innovation and geographic expansion driving double-digit growth in Sensodyne and parodontax. New launches such as Sensodyne Clinical Repair and expansion in markets like India and China have supported the category.

Haleon is also pushing into China's second- and third-tier cities, tailoring gum health products to local preferences. Solid oral health growth has helped offset weaker categories, and its momentum will be a key focus on Thursday.

Margins and Cost Pressures

Gross margin expansion has been a positive theme, driven by supply chain productivity programmes. That has allowed Haleon to invest more in advertising, promotion and research while still growing profits. However, higher energy and transport costs linked to the Middle East conflict could pressure input costs.

Currency movements also matter, as Haleon earns a large share of revenue outside the UK. Sterling was steady around $1.33 on Budget day.

What Investors Are Watching Next

On 29 October, investors will focus on third-quarter organic revenue growth, the split between price and volume, regional performance in North America and emerging markets, and whether full-year guidance is reiterated. Comments on the start of the cold and flu season will be important for fourth-quarter expectations.

Further ahead, full-year results in early 2027 will provide guidance for the next year, along with updates on share buybacks and dividends.

How the Market May React

Consumer health stocks have been seen as defensive investments, but 2026 has shown that they are not immune to volatility. Weak cold and flu seasons, cautious US consumers and pricing pressure have all affected growth. Haleon's share price will likely respond to whether third-quarter organic growth shows clear acceleration from the first half.

A result in the middle of the 3% to 5% guidance range, with balanced price and volume growth, would likely be welcomed. A weaker figure, or a narrowing of guidance toward the lower end, could weigh on the shares, especially given the cautious mood toward healthcare after GSK's update. For Haleon (LSE:HLN), North America remains the most important single swing factor.

Outlook

Haleon (LSE:HLN) has a portfolio of trusted brands and a clear medium-term growth framework, but 2026 has started slowly. Thursday's statement will indicate whether growth is accelerating as planned. A steady update could help restore confidence in defensive consumer health stocks after a difficult week for the sector.